{
  "id": 21215384,
  "title": "Johnson & Johnson vs. Pfizer: Which Healthcare Stock Is a Better Buy for 2027?",
  "url": "https://urgent.news/2026/11/22/johnson-johnson-vs-pfizer-which-healthcare-stock-is-a-better-buy-for",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-22T13:05:02.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/coverage/better-buy/2026/11/22/johnson-johnson-vs-pfizer-which-healthcare-stock-is-a-better-buy-for-2027/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "Investors often gravitate towards the healthcare sector for long-term stability, but determining which titan among Johnson & Johnson (JNJ) and Pfizer (PFE) is the better buy for 2027 requires examining their distinct growth strategies. J&J operates through two primary segments: drug development and medical devices, while Pfizer is shifting its focus toward oncology and weight-loss treatments. J&J's medtech division is a significant player in medical device stocks, offering critical solutions for surgery, orthopedics, and vision, and they distribute products worldwide through wholesalers, hospitals, and partnerships. In 2026, J&J's revenue reached nearly $99.3 billion, with a net income of about $16.1 billion. Their debt-to-equity ratio was approximately 0.6, indicating a comfortable liquidity position. On the other hand, Pfizer is heavily investing in oncology and obesity pipelines, aiming to boost growth through acquisitions like Seagen. They developed oral treatments for weight loss and face legal and regulatory risks, including litigation and price negotiations under the Inflation Reduction Act. Pfizer's debt-to-equity ratio is roughly 0.8, with a current ratio of about 1.2. Over the past decade, both companies have underperformed the S&P 500, with Pfizer even dipping into the red. However, J&J stands out as a mature, dividend-paying giant with a 60-year streak of annual increases. While Pfizer offers a higher dividend yield, J&J provides steadier, long-term growth and stability. Therefore, J&J emerges as the more attractive stock for the coming years, offering both financial and operational resilience.",
  "summary": "Johnson & Johnson's drug-and-device product mix faces off against Pfizer's high-stakes oncology and obesity bets, with a valuation gap that may sway your choice.",
  "key_points": [
    "Johnson & Johnson focuses on drug development and medical devices, with a strong medtech division.",
    "Pfizer shifts focus to oncology and weight-loss treatments, investing in Seagen acquisition.",
    "J&J offers steady, long-term growth and stability, while Pfizer provides higher dividend yield."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}